InnovHeart key facts
as of Oct 2026- Developer of an implant technology designed to treat patients suffering from mitral valve disease.
- InnovHeart is valued at approximately $125.0M as of Oct 2026 (last reported valuation).
- It has raised $73.4M; the latest was Later Stage VC ($9.3M) in Dec 2025.
- Notable investors include CDP Venture Capital (Rome), Panakes Partners, Indaco Venture Partners, Enea Tech e Biomedical, ENEA Tech Biomedical — 7 tracked in total.
- Status: Privately Held (backing).
InnovHeart's last reported valuation, Dec 2025. Nothing priced has surfaced since.
- ·Watch InnovHeart: the Monday email on marks, rounds and moves
InnovHeart funding rounds
No funding rounds for InnovHeart are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
InnovHeart valuation
InnovHeart's last reported valuation was $125 million in Dec 2025. No priced round, secondary trade or fund mark has surfaced since.
InnovHeart investors
7 investors are on record for InnovHeart, including CDP Venture Capital (Rome), Panakes Partners, Indaco Venture Partners and Enea Tech e Biomedical.
About InnovHeart
Developer of an implant technology designed to treat patients suffering from mitral valve disease. The company's technology focuses on replacing mitral valves based on an easy-to-use transcatheter technology, enabling hospitals to treat patients suffering from heart valve dysfunction safely and effectively.
- Sector
- Healthcare
- HQ
- Milan, Italy
- Founded
- 2015
- Employees
- 25
- Website
- innovheart.com/
- Ownership
- Privately Held (backing)
Is this your company? Sign in with your work email to keep it current, or tell us what's wrong.